How Does SPRAVATO Work for Depression?
Watch: How SPRAVATO Works: The Glutamate System vs Typical Antidepressants

From the TMS Therapy Centers Colorado video series. Educational only; not medical advice.
Serotonin, norepinephrine, and dopamine, the chemical messengers that have been the focus of depression treatment for decades, are where most familiar antidepressants work. SPRAVATO works somewhere else. This article explains the mechanism in plain language, why it changes the timing of treatment, and what is and is not known. It comes from TMS Therapy Centers Colorado, a physician-led psychiatric clinic serving the Denver metro and all of Colorado.
Where SPRAVATO acts
Esketamine, the active ingredient in SPRAVATO, acts on the glutamate system, the brain's most abundant excitatory signaling network. It does so by blocking a receptor known as the NMDA receptor.
That is a different target from the serotonin-based medications most people have tried. It is one reason SPRAVATO can be considered when other medications have not been enough. You can read the basics on our what is SPRAVATO article.
The cascade after the block
Blocking the NMDA receptor sets off a cascade:
- A surge of glutamate signaling
- Activation of other receptors downstream
- A release of growth factors that encourage neurons to form further connections
Researchers refer to this as synaptic plasticity. The working theory is that depression thins out connections in regions involved in mood and motivation, while esketamine may help those connections regrow. It is a theory rather than a settled account, and it is worth treating it that way.
Why the timing feels different
This difference in mechanism is the reason the timing of SPRAVATO feels so different from a typical antidepressant. A serotonin-based medication usually needs several weeks of daily dosing before any shift in mood is noticeable.
Esketamine's effects on glutamate begin during the session itself. Some people describe noticing a change in mood within the first day or two, though others need several sessions and some do not respond. There is no way to know in advance which group a given person will fall into, and an honest evaluation says so.
Why sessions are spaced out
It is also why sessions are spaced out rather than daily. SPRAVATO is not taken at home every day like a pill. It is given in a certified setting with monitoring, on a schedule set by the treating psychiatrist. The SPRAVATO page explains the schedule and setting in more detail.
Why a person can stay on an oral antidepressant
A person can remain on an oral antidepressant while receiving SPRAVATO, because the two work through separate pathways. For adults with treatment-resistant depression, SPRAVATO is FDA-approved both with an oral antidepressant and as monotherapy since 2025. Whether to continue an oral antidepressant is a decision made at the evaluation, based on current medications, side effects, and history.
What the dissociation is
The dissociation some people feel during a session, a sense of being detached or floaty, is a direct result of the NMDA receptor block. It generally fades within the monitoring period. People are monitored throughout so that the experience can be watched and supported. For many, knowing in advance that the sensation is expected and temporary makes it easier to tolerate.
What is understood and what is not
Nobody fully understands every step of how esketamine lifts depression. What is understood well enough to act on is that it offers a mechanism unlike anything in the standard antidepressant toolkit. That is precisely why it earned an FDA approval for treatment-resistant depression in adults.
It would be inaccurate to claim more. The glutamate and plasticity explanations are working theories, and ongoing research continues to refine them. A treatment can be effective for many people while its mechanism is still being worked out, and that is true of several treatments in psychiatry.
SPRAVATO compared with other approaches
Different treatments act through different routes. Medications such as serotonin-based antidepressants work through chemical messengers. Transcranial magnetic stimulation uses magnetic pulses to stimulate a targeted brain region, and is FDA-cleared for major depressive disorder. You can read about it on our TMS therapy page. SPRAVATO acts through glutamate. Having more than one mechanism available is part of why a person who has not responded to one approach may still respond to another.
Why mechanism matters to patients
For someone who has tried several medications without enough relief, hearing that a treatment works through a different system can be meaningful. It suggests that the earlier lack of response does not predict what will happen here. That is a reasonable basis for hope, though not a promise. Response differs from person to person, and a trial of SPRAVATO is a trial, with progress measured at regular points so decisions rest on how symptoms are actually tracking.
Is it the right mechanism for you
Whether that mechanism is the right one for a particular person is a question for a psychiatric evaluation. The evaluation reviews past medications, current symptoms, medical history, and preferences. It also considers practical factors such as the need for a ride home after each session.
What to bring to an evaluation
It helps to arrive with:
- A list of medications you have tried, with doses and durations if you remember them
- A note on how long the current episode has lasted
- Any medical conditions, especially blood pressure
- Questions about schedule and monitoring
How care works at TMS Therapy Centers Colorado
TMS Therapy Centers Colorado was founded by William Kromka, MD, a board-certified psychiatrist. A first evaluation can happen in person or by secure video anywhere in Colorado, and no referral is needed. Most major insurance plans are accepted, and benefits are verified and prior authorization is handled before treatment begins. To begin, call 720-500-7873.